Kevin Schmid is a prominent engineering and business professional with a rich and diverse background in the pharmaceutical and medical device industries. He holds a Bachelor of Science in Mechanical Engineering from Clarkson University and an MBA from Sacred Heart University in Connecticut.

Schmid has served in executive and advisory roles at several innovative healthcare companies. He is currently the Chief Executive Officer at Common Sensing, a Cambridge-based company that creates disposable injector pen dose monitoring and reporting technology. Additionally, since January 2018, he has been serving as a member of the board of directors for Sorrel Medical Ltd., an Israeli-based company that develops wearable, pre-filled cartridge-based drug delivery platform technology.

Before joining Common Sensing and Sorrel Medical, Schmid worked as a Vice President of Drug Delivery Systems at the Stevanato Group, a provider of innovative packaging and drug delivery solutions for the pharmaceutical industry. From 2011 to 2015, he was Vice President of Business Development and Advanced Technology at Insulet Corporation, a medical device company specializing in diabetes management systems. During his tenure, Schmid played a crucial role in developing, industrializing, and commercializing the Omnipod Diabetes Management System, among other projects.

Throughout his career, Schmid has held various technical and leadership roles at JDS Uniphase Corporation, Bose Corporation, American Cyanamid, and BIC Corporation. In each case, he has leveraged his expertise in advanced product and manufacturing technology to drive innovation, improve quality, and enhance overall performance.

Overall, Kevin Schmid is a highly accomplished healthcare industry professional with a track record of success in engineering, operations, business development, and leadership.